Jason E. Hawkes, MD, MS

Understanding urticaria subtypes, from spontaneous to inducible, is key to crafting patient-specific management plans.

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

Hawkes combines personal experience and clinical expertise to treat urticaria patients.

Hawkes shared his excitement for the near future of dermatology, recognizing the increasing ability to provide tailored care to patients.

Hawkes highlighted how second-generation TYK2 inhibitors improve upon earlier oral therapies with greater efficacy and selectivity.

Hawkes highlighted the intersection of oncology and dermatology, focusing on immune checkpoint inhibitors and their cutaneous adverse events.

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

During his session at Maui Derm NP+PA Fall, Hawkes emphasized the need for careful patient communication and shared his excitement for remibrutinib.

Hawkes highlights groundbreaking therapies for psoriasis, including new oral medications and IL-23 inhibitors.

Jason Hawkes, MD, MS, detailed each of the kinases' association with different cytokine receptors and biological functions.

Jason Hawkes, MD, MS, breaks down boxed warning pros and cons and research addressing several boxed warnings.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.